Pet Age-Related Disease Treatments Advance
Owners of aging dogs and cats may one day have new options for heart, muscle, and kidney conditions, though none are yet available.
Updated on Nov. 4, 2026 in Pet Health
Live Poll
Would you pay for an expensive gene therapy to extend your pet's life?
Several companies are developing treatments for age-related diseases in pets, including gene therapies aimed at heart disease, lifespan extension, and muscle loss in dogs, and drugs for muscle loss and kidney disease in cats. Rejuvenate Bio, based in San Diego, California, is developing a gene therapy for mitral valve disease, the most common heart condition in dogs.
Why it matters
Pet owners facing age-related illness in dogs and cats may see new treatment options emerge from this research, though the work remains in development. The efforts reflect growing interest in extending the healthy life of companion animals, which could eventually affect veterinary costs and care decisions for households.
Rejuvenate Bio is developing a gene therapy for mitral valve disease, the most common heart condition in dogs, while Genflow Biosciences is developing gene therapies for lifespan extension and age-related muscle loss. The Cat Health Company, based in Bucharest, has two compounds in clinical trials targeting muscle loss and kidney disease in cats.
The players
Rejuvenate Bio
A San Diego, California company developing a gene therapy for mitral valve disease in dogs, with a focus on lowering the cost of gene therapy production.
Genflow Biosciences
A company developing gene therapies aimed at extending dogs' lifespans and reducing age-related muscle loss.
The Cat Health Company
A Bucharest-based company developing drugs for muscle loss and kidney disease in cats, with two compounds in clinical trials.
The details
Rejuvenate Bio has worked to reduce the cost of producing gene therapies, which are complex treatments, a step that could make such options more accessible if the approach succeeds. Genflow Biosciences is targeting sarcopenia, the age-related loss of muscle, with its gene therapy. Companies are also exploring probiotic pet food and medicines originally developed for humans, extending approaches from human medicine into veterinary care.
Timeline
No specific dates or timeframes were stated in the source.
The Home Front
Efforts to treat age-related disease in pets extend approaches first developed for human medicine, such as gene therapy and human-origin probiotics, into the veterinary market. These developments sit alongside a growing pet-care economy in which owners increasingly seek longer and healthier lives for their animals.
If you have an aging dog or cat, keep up with scheduled veterinary checkups so that heart, kidney, and muscle changes are caught early. Ask your vet whether your pet's breed or condition is a candidate for any emerging treatment, since most of these therapies remain in development and are not yet widely available.
The takeaway
Treatments for age-related pet disease are moving from concept toward clinical testing, but none are yet a standard option for pet owners. Keep a running list of your pet's health conditions and bring it to your veterinarian at each visit so you are ready to discuss new options as they arrive.
Further reading
For more on the care side of this research, explore our coverage of Pet Health and how treatment advances are changing routine veterinary decisions for households.
Source note: This article includes information reported by Qazinform.
Live Poll
Would you pay for an expensive gene therapy to extend your pet's life?
